Safety Study of IL-21/Ipilimumab Combination in the Treatment of Melanoma

NCT01489059 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

42

Enrollment

INDUSTRY

Sponsor class

Conditions

Melanoma

Interventions

BIOLOGICAL: BMS-982470 (recombinant interleukin-21)
BIOLOGICAL: BMS-982470 (recombinant interleukin-21)
BIOLOGICAL: BMS-982470 (recombinant interleukin-21)
BIOLOGICAL: BMS-982470 (recombinant interleukin-21)
BIOLOGICAL: Ipilimumab
BIOLOGICAL: Ipilimumab
BIOLOGICAL: Ipilimumab

Sponsor

Bristol-Myers Squibb